| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Krystyna Stepień, Anna Dzierzega-Lecznar, Irena Ta. [The role of neuromelanin in Parkinson's disease--new concepts]. Wiadomosci lekarskie (Warsaw, Poland : 1960). vol 60. issue 11-12. 2016-04-23. PMID:18540183. |
progressive degeneration of dopaminergic neurons of the substantia nigra and the resulting dopamine deficiency in the striatum are neuropathological basis of the movement disorders in parkinson's disease (pd). |
2016-04-23 |
2023-08-12 |
Not clear |
| Yang Li, Peter S Hasenhuetl, Klaus Schicker, Harald H Sitte, Michael Freissmuth, Walter Sandtne. Dual Action of Zn2+ on the Transport Cycle of the Dopamine Transporter. The Journal of biological chemistry. vol 290. issue 52. 2016-04-22. PMID:26504078. |
the dopamine transporter shapes dopaminergic neurotransmission by clearing extracellular dopamine and by replenishing vesicular stores. |
2016-04-22 |
2023-08-13 |
Not clear |
| Bo Zhang, Kun Ma, Baixiang L. Inflammatory reaction regulated by microglia plays a role in atrazine-induced dopaminergic neuron degeneration in the substantia nigra. The Journal of toxicological sciences. vol 40. issue 4. 2016-04-19. PMID:26165640. |
increasing evidence indicates that atr plays a critical role in inducing physiological changes to the endocrine and reproductive systems, and further may affect the nigrostriatal dopaminergic system in the diencephalon, resulting in altered dopamine (da) levels in the striatum, transport and storage-related protein abnormalities in the synaptic terminals, motor function deficits, and degeneration of da neurons in the substantia nigra (sn). |
2016-04-19 |
2023-08-13 |
rat |
| Brittany Butler, Kaustuv Saha, Tanu Rana, Jonas P Becker, Danielle Sambo, Paran Davari, J Shawn Goodwin, Habibeh Khoshboue. Dopamine Transporter Activity Is Modulated by α-Synuclein. The Journal of biological chemistry. vol 290. issue 49. 2016-04-19. PMID:26442590. |
the duration and strength of the dopaminergic signal are regulated by the dopamine transporter (dat). |
2016-04-19 |
2023-08-13 |
Not clear |
| Stefanie Seiler, Stefano Di Santo, Hans Rudolf Widme. Nogo-A Neutralization Improves Graft Function in a Rat Model of Parkinson's Disease. Frontiers in cellular neuroscience. vol 10. 2016-04-19. PMID:27092052. |
transplantation of fetal human ventral mesencephalic (vm) dopaminergic neurons into the striatum is a promising strategy to compensate for the characteristic dopamine deficit observed in parkinson's disease (pd). |
2016-04-19 |
2023-08-13 |
human |
| Jin Li, Yue Cui, Karen Wu, Bing Liu, Yun Zhang, Chao Wang, Tianzi Jian. The cortical surface area of the insula mediates the effect of DBH rs7040170 on novelty seeking. NeuroImage. vol 117. 2016-04-15. PMID:26003854. |
we focused on the dbh gene because it encodes a key enzyme for dopamine metabolism, ns is believed to be related to the dopaminergic system and has been reported associated with dbh variation. |
2016-04-15 |
2023-08-13 |
human |
| Eva Vergaño-Vera, Eva Díaz-Guerra, Eva Rodríguez-Traver, Héctor R Méndez-Gómez, Óscar Solís, Jaime Pignatelli, James Pickel, Sang-Hun Lee, Rosario Moratalla, Carlos Vicario-Abejó. Nurr1 blocks the mitogenic effect of FGF-2 and EGF, inducing olfactory bulb neural stem cells to adopt dopaminergic and dopaminergic-GABAergic neuronal phenotypes. Developmental neurobiology. vol 75. issue 8. 2016-04-12. PMID:25447275. |
our results indicate that nurr1 overexpression in obscs induces the formation of two populations of mature dopaminergic neurons with features of the ventral mesencephalon or of the ob, capable of responding to functional dopaminergic stimuli and of releasing dopamine. |
2016-04-12 |
2023-08-13 |
mouse |
| Sandy Stayte, Peggy Rentsch, Kong M Li, Bryce Visse. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease. PloS one. vol 10. issue 4. 2016-04-12. PMID:25902062. |
parkinson's disease (pd) is a chronic neurodegenerative disease characterized by a significant loss of dopaminergic neurons within the substantia nigra pars compacta (snpc) and a subsequent loss of dopamine (da) within the striatum. |
2016-04-12 |
2023-08-13 |
mouse |
| Anabel Molero, Marc Vendrell, Jordi Bonaventura, Julian Zachmann, Laura López, Leonardo Pardo, Carme Lluis, Antoni Cortés, Fernando Albericio, Vicent Casadó, Miriam Roy. A solid-phase combinatorial approach for indoloquinolizidine-peptides with high affinity at D(1) and D(2) dopamine receptors. European journal of medicinal chemistry. vol 97. 2016-04-12. PMID:25969169. |
specifically, compounds able to bind at d1r and d2r with high affinity could restore the effects of dopamine depletion and enhance motor activation on degenerated nigrostriatal dopaminergic systems. |
2016-04-12 |
2023-08-13 |
Not clear |
| Wei Ma, Hui-Ting Liu, Yi-Tao Lon. Monitoring Dopamine Quinone-Induced Dopaminergic Neurotoxicity Using Dopamine Functionalized Quantum Dots. ACS applied materials & interfaces. vol 7. issue 26. 2016-04-12. PMID:26070031. |
monitoring dopamine quinone-induced dopaminergic neurotoxicity using dopamine functionalized quantum dots. |
2016-04-12 |
2023-08-13 |
Not clear |
| Wei Ma, Hui-Ting Liu, Yi-Tao Lon. Monitoring Dopamine Quinone-Induced Dopaminergic Neurotoxicity Using Dopamine Functionalized Quantum Dots. ACS applied materials & interfaces. vol 7. issue 26. 2016-04-12. PMID:26070031. |
dopamine (da) quinone-induced dopaminergic neurotoxicity is known to occur due to the interaction between da quinone and cysteine (cys) residue, and it may play an important a role in pathological processes associated with neurodegeneration. |
2016-04-12 |
2023-08-13 |
Not clear |
| Nevein Ibrahim, Joanna Kusmirek, Aaron F Struck, John M Floberg, Scott B Perlman, Catherine Gallagher, Lance T Hal. The sensitivity and specificity of F-DOPA PET in a movement disorder clinic. American journal of nuclear medicine and molecular imaging. vol 6. issue 1. 2016-04-12. PMID:27069770. |
(18)f-dopa l-6-[(18)f] fluoro-3,4-dihydroxyphenylalnine ((18)f-dopa) is a positron emission tomography (pet) agent that measures the uptake of dopamine precursors for assessment of presynaptic dopaminergic integrity and has been shown to accurately reflect the monoaminergic disturbances in pd. |
2016-04-12 |
2023-08-13 |
Not clear |
| Ashley L Green, Muhammad M Hossain, Siew C Tee, Helmut Zarbl, Grace L Guo, Jason R Richardso. Epigenetic Regulation of Dopamine Transporter mRNA Expression in Human Neuroblastoma Cells. Neurochemical research. vol 40. issue 7. 2016-04-11. PMID:25963949. |
the dopamine transporter (dat) is a key regulator of dopaminergic neurotransmission. |
2016-04-11 |
2023-08-13 |
human |
| Alberto Avila-Luna, Jacqueline Prieto-Leyva, Arturo Gálvez-Rosas, Alfonso Alfaro-Rodriguez, Rigoberto Gonzalez-Pina, Antonio Bueno-Nav. D1 Antagonists and D2 Agonists Have Opposite Effects on the Metabolism of Dopamine in the Rat Striatum. Neurochemical research. vol 40. issue 7. 2016-04-11. PMID:25981954. |
we have previously shown that selective inhibition of d1rs increases the dopaminergic metabolic response and proposed that this effect is associated with the concomitant activation of postsynaptic d2rs by endogenous dopamine (da). |
2016-04-11 |
2023-08-13 |
rat |
| Justin Davis, Steven Moylan, Brian H Harvey, Michael Maes, Michael Ber. Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries. The Australian and New Zealand journal of psychiatry. vol 48. issue 6. 2016-04-08. PMID:24803587. |
whilst dopaminergic dysfunction remains a necessary component involved in the pathogenesis of schizophrenia, our current pharmacological armoury of dopamine antagonists does little to control the negative symptoms of schizophrenia. |
2016-04-08 |
2023-08-13 |
Not clear |
| Perdita Cheshire, Scott Ayton, Kelly L Bertram, Helen Ling, Abi Li, Catriona McLean, Glenda M Halliday, Sean S O'Sullivan, Tamas Revesz, David I Finkelstein, Elsdon Storey, David R William. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. Movement disorders : official journal of the Movement Disorder Society. vol 30. issue 6. 2016-04-07. PMID:25649148. |
we obtained brain tissue from 44 pd cases and 17 age-matched controls and assessed monoamine levels and the serotonin and dopamine transporters in the striatum, and the extent of dopaminergic and serotonergic cell preservation in the substantia nigra (sn) and the dorsal raphe nuclei (drn), respectively. |
2016-04-07 |
2023-08-13 |
Not clear |
| Perdita Cheshire, Scott Ayton, Kelly L Bertram, Helen Ling, Abi Li, Catriona McLean, Glenda M Halliday, Sean S O'Sullivan, Tamas Revesz, David I Finkelstein, Elsdon Storey, David R William. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. Movement disorders : official journal of the Movement Disorder Society. vol 30. issue 6. 2016-04-07. PMID:25649148. |
as expected, pd patients demonstrated a severe loss of all dopaminergic markers, including dopamine (p < 0.0001) and the dopamine transporter (p < 0.0001) in the striatum, and dopaminergic neurons (p < 0.001) in the sn, compared with controls. |
2016-04-07 |
2023-08-13 |
Not clear |
| Francesco Porta, Alberto Ponzone, Marco Spad. Short prolactin profile for monitoring treatment in BH4 deficiency. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. vol 19. issue 3. 2016-04-07. PMID:25707872. |
according to the finding that dopamine is the natural inhibitor of prolactin (prl) incretion, we introduced the use of peripheral prl measurement as an index of dopaminergic homeostasis, so avoiding the need of repeated lumbar punctures in patients with bh4 deficiency. |
2016-04-07 |
2023-08-13 |
Not clear |
| Francesco Porta, Alberto Ponzone, Marco Spad. Short prolactin profile for monitoring treatment in BH4 deficiency. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. vol 19. issue 3. 2016-04-07. PMID:25707872. |
together with the assessment of patients' clinical symptoms, this standardized tool will ensure an objective non-invasive reference to the management of dopaminergic replacement therapy in bh4 deficiency, even in patients treated with dopamine agonists. |
2016-04-07 |
2023-08-13 |
Not clear |
| Kazuko Takahashi-Niki, Ayako Inafune, Naruyuki Michitani, Yoshitaka Hatakeyama, Kotaro Suzuki, Mai Sasaki, Yoshihisa Kitamura, Takeshi Niki, Sanae M M Iguchi-Ariga, Hiroyoshi Arig. DJ-1-dependent protective activity of DJ-1-binding compound no. 23 against neuronal cell death in MPTP-treated mouse model of Parkinson's disease. Journal of pharmacological sciences. vol 127. issue 3. 2016-04-05. PMID:25837927. |
parkinson's disease (pd) is caused by dopaminergic cell death in the substantia nigra, leading to a reduced level of dopamine in the striatum. |
2016-04-05 |
2023-08-13 |
mouse |